GE HealthCare, the GE HealthCare Foundation, and the Charles Antetokounmpo Family Foundation Commit $1M to Improve Milwaukee Health Outcomes
GE HealthCare Announces Major Academic Medical Center as First Customer to Adopt New Hospital Pulse Tile for Command Center
BTIG Maintains GE HealthCare Technologies(GEHC.US) With Buy Rating, Maintains Target Price $100
GE Healthcare Technologies Inc's Flyrcado Gains Buy Rating Amid FDA Approval and Revenue Growth Potential
GE HealthCare Technologies To Go Ex-Dividend On October 18th, 2024 With 0.03 USD Dividend Per Share
October 16th (Eastern Time) - $GE HealthCare Technologies(GEHC.US)$ is trading ex-dividend on October 18th, 2024.Shareholders of record on October 18th, 2024 will receive 0.03 USD dividend per share
A New Theranostics Center of Excellence in Europe: GE HealthCare and University Medicine Essen Collaborate to Advance Theranostics and Personalized Medicine
Canada (Biplane and Single Plane) Angio Suites Market Analysis and Outlook, 2018-2033, Featuring Siemens Healthineers, GE HealthCare Technologies, Philips Healthcare Informatics & More
GE HealthCare's Shares Rise After the Launch of Versana Premier
GE HealthCare Introduces Easy-to-use, Easy-to-learn, Easy-to-diagnose Versana Premier Multi-purpose Ultrasound System
Jim Cramer on GE HealthCare Technologies Inc. (GEHC): 'I'd Wait For Another Downgrade And Buy More'
GE HealthCare Acquires Intelligent Ultrasound's Clinical AI Business
Jim Cramer Lists 10 Stocks on the S&P 500 That Notched the Biggest Gains in the Past Two Years
GEHC's MIM Software to Aid Radiation Therapy With Its Latest FDA Nod
Jim Cramer Likes Reddit Very Much, Calls Accenture A 'Great Buy'
GE HealthCare Accelerates Artificial Intelligence Adoption With New Offering to Advance Enterprise Imaging
Press Release: GE HealthCare to Announce Third Quarter 2024 Results on October 30, 2024
Goldman Sachs Adjusts Price Target on GE HealthCare Technologies to $91 From $88
GE HealthCare Takes Key Role in New Consortium to Revolutionize Cancer Care, Advancing Precision Medicine for Patients in Europe
Buy Rating for GE Healthcare Technologies Inc. on Flyrcado's Market Disruption Potential
GE HealthCare Announces Phase I Results for a First-of-its-Kind Macrocyclic Manganese-Based MRI Contrast Agent